Perhaps the differential role of insulin and IGF-1 in prostate cancer development vs. castration resistance is one of the underlying reasons for the failure of cixutumumab (a monoclonal antibody that targets IGF-1R) to improve time to castration resistance in metastatic prostate cancer [26] (an almost identical cohort to our patient cohort). This evidence concerns the gene IGF1 and prostate cancer.